OverviewSuggest Edit

Xenikos is a clinical-stage biopharmaceutical company. It develops immunotherapies based on the action of toxin-conjugated antibodies for patients suffering immune diseases, or rejection after transplantation.
HQNijmegen, NL

Latest Updates

Employees (est.) (Jul 2021)13
Cybersecurity ratingAMore

Key People/Management at Xenikos

Ypke van Oosterhout

Ypke van Oosterhout

Founder and Chief Executive Officer, Director
Douglas E. Williams

Douglas E. Williams

Chairman of the Board, Non-Executive Director
Maarten Frijlink

Maarten Frijlink

Chief Operating Officer
Jake Simson

Jake Simson

Non-Executive Director
Eric van Hooren

Eric van Hooren

Chief Development Officer
Viktor Mattousch

Viktor Mattousch

Board Observer
Show more

Xenikos Office Locations

Xenikos has an office in Nijmegen
Nijmegen, NL (HQ)
Wilhelminasingel 14
Show all (1)

Xenikos Financials and Metrics

Summary Metrics

Founding Date


Xenikos total Funding

$37 m

Xenikos latest funding size

$30 m

Time since last funding

3 years ago

Xenikos investors

Xenikos's latest funding round in May 2018 was reported to be $30 m. In total, Xenikos has raised $37 m
Show all financial metrics

Xenikos Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Xenikos Online and Social Media Presence

Embed Graph

Xenikos News and Updates

Xenikos Announces T-Guard® Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives

Company Plans to Commence New Pivotal, Randomized Phase 3 Study Evaluating T-Guard® Versus Ruxolitinib in Patients with Grade III or IV Steroid-refractory Acute Graft-Versus-Host Disease in Second Half of 2021

Xenikos Blogs

Xenikos Announces T-Guard Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives

Het bericht Xenikos Announces T-Guard Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives verscheen eerst op Xenikos - Resetting the immune system.

Xenikos Frequently Asked Questions

  • When was Xenikos founded?

    Xenikos was founded in 2012.

  • Who are Xenikos key executives?

    Xenikos's key executives are Ypke van Oosterhout, Douglas E. Williams and Maarten Frijlink.

  • How many employees does Xenikos have?

    Xenikos has 13 employees.

  • Who are Xenikos competitors?

    Competitors of Xenikos include Pliant Therapeutics, Rome Therapeutics and Quellis Biosciences.

  • Where is Xenikos headquarters?

    Xenikos headquarters is located at Wilhelminasingel 14, Nijmegen.

  • Where are Xenikos offices?

    Xenikos has an office in Nijmegen.

  • How many offices does Xenikos have?

    Xenikos has 1 office.